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Conclusions: In patients with atrial ﬁbrillation and vascular disease,
the addition of antiplatelet therapy to vitamin K antagonist therapy
(VKA) is not associated with additional beneﬁt in thromboembolic or cor-
onary risk, but does increase bleeding risk.
Summary: Arterial thrombi are considered different from those
originating in the veins and the atria. Arterial thrombi are thought to
be primarily dependent on platelet mechanisms and are so-called white
thrombi. Antiplatelet agents therefore are the mainstay of therapy for
patients with peripheral arterial disease and coronary disease. On the
other hand, thrombi originated in veins and in the atria form in a
low-pressure environment and are rich in ﬁbrin and trapped erythro-
cytes forming a so-called red clot. The mainstay of therapy for these
types of thrombi is antithrombotic therapy, generally vitamin K antago-
nists. Obviously, however, many patients with arterial disease of the pe-
ripheral of coronary circulations also have venous disease or atrial
ﬁbrillation and are treated with a combination of anti-platelet agents
and antithrombotic agents in an effort to mitigate the risk from both
types of thrombi. However, there is little evidence of a favorable bio-
logic effect of such combination antithrombotic therapy on thrombo-
embolic events and there is a potential increase in serious bleeding
(Sorensen R et al, Lancet 2009;374:1967-74). The objective of this
current study was to investigate the impact of atrial ﬁbrillation (AF)
and antithrombotic treatment on prognosis in patients with heart failure
(HF) as well as those with vascular disease. In this study, patients hos-
pitalized with heart failure and coexisting vascular disease, either coro-
nary artery disease or peripheral arterial disease, were followed from
1997 to 2009. AF status was categorized as prevalent AF, incident
AF, or no AF. Risk of thromboembolism (TE), myocardial infarction
(MI), and serious bleeding was assessed by Cox regression models
(hazard ratio [HR] with 95% conﬁdence interval [CI]) with antithrom-
botic therapy and AF as time-dependent variables. A total of 37,464 pa-
tients were included in the study, with a mean age of 74.5 6 10.7 years
and 36.3% female. Mean follow-up was 3 years during which 20.7% of
patients were categorized as prevalent AF and 17.2% as incident AF.
Compared with vitamin K antagonist (VKA) in prevalent AF, VKA
plus antiplatelet therapy was not associated with a decreased risk of
thromboembolism (HR, 0.91; 95% CI, 0.73-1.12) or MI (HR, 1.11;
95% CI, 0.96-1.28). Bleeding risk, however, was signiﬁcantly increased
(HR, 1.31; 95% CI, 1.09-1.57). Corresponding estimates for incident
AF were HR of 0.77 (95% CI, 0.56-1.06), 1.07 (95% CI, 0.89-1.28),
and 2.71 (95% CI, 1.33-2.21) for TE, MI, and bleeding respectively.
In no AF patients there were no statistical differences seen, between
antithrombotic therapies and TE or MI risk whereas bleeding risk was
signiﬁcantly increased with VKAs with and without single-antiplatelet
therapy.
Comment: Many vascular disease patients are on combinations of
vitamin K antagonists and oral antiplatelet agents. One would potentially
like to extrapolate this data to vascular surgical patients. However, the
majority of vascular patients on a combination of antiplatelet and
vitamin K antagonist therapy do not speciﬁcally fall within the types of
patients examined in this study. In addition, it is very likely that oral
anticoagulation agents that directly inhibit factor Xa or thrombin will
become more widely utilized than vitamin K antagonists. Because these
oral agents are associated with a decreased risk of bleeding compared to
vitamin K antagonists the risk beneﬁt ratio of combining a thrombin in-
hibitor or a Xa inhibitor with an antiplatelet agent may be quite different
than a combination of vitamin K antagonists and antiplatelet agents.
Modern trials will be needed to determine the outcome of management
of patients with peripheral and/or coronary arterial disease in combina-
tion with either venous disease or atrial ﬁbrillation. The paper leads one
to think that there may be coming a paradigm shift in management of
the thrombus in patients with combinations of arterial disease and
venous disease or atrial ﬁbrillation.804Time-Dependent Changes in Atherosclerotic Plaque Composition in
Patients Undergoing Carotid Surgery
van Lammeren GW, den Ruijter HM, Vrijenhoek JE, et al. Circulation
2014;129:2269-76.
Conclusions: Over the past decade, atherosclerotic plaques harvested
during carotid endarterectomy demonstrate a time-dependent change in
plaque composition characterized by a decrease in plaque features felt to
be related to plaque instability.
Summary: Comparison studies have provided insights into athero-
sclerotic plaque characteristics associated with cardiovascular event. How-
ever, to date there has been no report of temporal changes in plaque
phenotypes during the last decade which coincides with a decreased inci-
dence of cardiovascular disease in high- income countries. The Athero-Ex-
press study is an ongoing longitudinal, vascular biobank study that includes
the collection of atherosclerotic plaques of patients undergoing primary ca-
rotid endarterectomy in the providence of Utrecht of the Netherlands
from 2002 to 2011. The authors utilized more than 1500 plaques
removed during carotid endarterectomy as part of the Athero-Express
study from 2002 to 2011. Histopathologic features of plaques of 1583 pa-
tients were analyzed in intervals of 2 years. This included an analysis and
quantiﬁcation of collagen, calciﬁcations, lipid cores, plaque thrombosis,
macrophages, smooth muscle cells, and microvessels. Large atheroma, pla-
que thrombosis, macrophages, and calciﬁcations were less frequently
observed over time with adjusted odds ratios of 0.72 (95% CI, 0.650-
0.789), 0.62 (95% CI, 0.569-0.679), 0.87 (95% CI, 0.800-0.940), and
0.75 (95% CI, 0.692-0.816) for 2-year increase in time, respectively.
Changes in plaque characteristics were consistently observed in patient
subgroups presenting with stroke, transient ischemic attack, ocular symp-
toms, and in asymptomatic patients. Concomitantly, risk factor manage-
ment and secondary prevention strategies among vascular patients
scheduled for carotid endarterectomy signiﬁcantly improved over the
past decade.
Comment: The data suggest an improvement in management of
atherosclerotic risk factors is resulting in a changing of the nature of athero-
sclerotic plaques at the carotid bifurcation. Not only may medical manage-
ment of atherosclerotic risk factors decrease the incidence and prevalence of
atherosclerotic plaques, it may also improve the characteristics of the plaques
with a lesser incidence of plaque features associated with plaque instability
and rupture.
Comparison of Three Ultrasound Methods of Measuring the Diameter
of the Abdominal Aorta
Gürtelschmid M, Björck M, Wanhainen A. BJS 2014;101:633-6.
Conclusions: The data indicates that leading edge method is the most
reproducible method of measuring the diameter of the abdominal aorta, and
all methods have a high degree of variability.
Summary: Ultrasound is the usual technique for screening and sur-
veillance of small abdominal aortic aneurysms (AAA). There is however
known inter observer and intra observer variability leading to variations
of diameter measurements of 0.5 cm or more. Some of this variability
may be due to different techniques of measuring the diameter of the
aorta. Different basic techniques exist: measuring outer-to-outer wall
(OTO), inner-to-inner wall (ITI). For OTO, calipers are placed on
the outer layer of the aortic wall, and for the ITI method calipers are
placed on the inner layer of the aortic wall. A third method is so-called
the leading edge-to-leading edge (LELE) technique. In this method cal-
ipers are placed on the outer wall of the anterior wall and the inner layer
of the posterior wall. There exists no consensus as to what method is
best to use and, in addition, different trials have used different methods
of measurement. The UK Small Aneurysm Trial using the OTO method
(Eur J Vasc Endovasc Surg 1995;9:42-8). The Multicenter Aneurysm
Screening Study used the ITI method (Lancet 2002;360:1531-9), and
the Tromosø study used the LELE method (Eur J Vasc Endovasc
Surg 1998;15:497-504). In this study the authors sought to determine
the variability and reliability of OTO vs LELE and ITI in a clinical
